Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 5/20 | 0.54 |
| ▸ | EGFR | P00533 | 3/20 | 0.54 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.51 |
| ▸ | ABL1 | P00519 | 2/20 | 0.50 |
| ▸ | ABL2 | P42684 | 2/20 | 0.50 |
| ▸ | PIK3CD | O00329 | 5/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.42 |
| ▸ | TNF | P01375 | 2/20 | 0.41 |
| ▸ | LITAF | Q99732 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL515118 | 1.00 | SRC (0.54) | SRCEGFRGPR119ABL1ABL2 | |
| SCHEMBL13861581 | 0.94 | SRC (0.48) | SRCEGFRGPR119ABL1ABL2 | |
| SCHEMBL13861580 | 0.94 | SRC (0.48) | SRCEGFRGPR119ABL1ABL2 | |
| SCHEMBL515111 | 0.94 | GPR119 (0.57) | SRCEGFRGPR119ABL1ABL2 | |
| SCHEMBL26811380 | 0.91 | GPR119 (0.46) | SRCEGFRGPR119ABL1ABL2 | |
| SCHEMBL1442019 | 0.84 | SLC22A12 (0.40) | SRCEGFRGPR119 | |
| SCHEMBL12395349 | 0.82 | GPR119 (0.46) | GPR119 | |
| SCHEMBL29927091 | 0.82 | SRC (0.57) | SRCEGFRGPR119ABL1ABL2 | |
| SCHEMBL28902638 | 0.82 | SRC (0.57) | SRCEGFRGPR119ABL1ABL2 | |
| SCHEMBL28902640 | 0.82 | SRC (0.57) | SRCEGFRGPR119ABL1ABL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120165310-A1 | ETHER DERIVATIVES OF BICYCLIC HETEROARYLS | NOVARTIS AG (CH) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165310-A1 | ETHER DERIVATIVES OF BICYCLIC HETEROARYLS | ETV6, CYP11B2, CYP11B1 | SRC 292/4885EGFR 132/4885GPR119 1396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.